Novo Nordisk B – Recent Developments
European Union Approval of Wegovy Tablet
On 16 July 2026, the European Commission granted Novo Nordisk approval for the oral semaglutide tablet, marketed as Wegovy. The new formulation delivers a daily dose of 25 mg and is intended for adults with obesity or overweight conditions. The approval expands the company’s obesity segment and provides a more convenient alternative to the existing injectable product.
Positive Long‑Term Data for Hemophilia Candidate
Earlier in the month, Novo Nordisk reported encouraging long‑term data for its hemophilia candidate Denecimig. The study results received attention in the German‑language press, indicating sustained efficacy and a favorable safety profile over extended treatment periods. These findings support the company’s broader biopharmaceutical pipeline.
Market Reaction and Analyst Adjustments
- Handelsbanken increased its target price for Novo Nordisk to 365 DKK (previously 350 DKK), reaffirming a buy recommendation.
- European equity markets opened with a modest decline in technology sectors, but Novo Nordisk shares were largely insulated from the broader sell‑off, reflecting the positive sentiment surrounding the new product launch.
Financial Context
- Close price (14 Jul 2026): 330.6 DKK
- 52‑week high (27 Jul 2025): 464.6 DKK
- 52‑week low (1 Mar 2026): 224.25 DKK
- Market capitalization: 1 451 679 940 608 DKK
- Price‑to‑earnings ratio: 11.67
The company’s market‑capitalization and price‑earnings metrics remain consistent with its status as a leading player in the health‑care sector, particularly within pharmaceuticals focused on diabetes care, obesity, and biopharmaceuticals.
Summary
Novo Nordisk’s recent milestones—European approval of the Wegovy tablet and positive long‑term data for Denecimig—have reinforced investor confidence. Analyst upgrades and a stable share price amid broader market volatility underscore the company’s solid position within the pharmaceutical industry.
